Trilaciclib plus chemo for certain solid tumors
Part of Cancer clinical trials.
This trial tests trilaciclib, a drug that may protect healthy cells during chemotherapy, in people with solid tumors that depend on CDK4/6 proteins. The goal is to see if it helps reduce side effects when given before chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor that is driven by CDK4/6 proteins
- Your doctor decides you need trilaciclib as a first prevention (based on a special model)
- You are not already taking trilaciclib for a different reason
- You are able to receive chemotherapy as part of your treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called trilaciclib, which is added to standard chemotherapy given before breast cancer surgery. The goal is to see if it helps shrink the tumor and possibly reduces side effects like low blood cell counts, making the treatment easier to tolerate.
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
This trial tests a drug that may help protect your bone marrow during chemotherapy, possibly reducing side effects like low blood counts. It is for people with certain advanced or recurrent solid tumors who are about to start a specific chemo regimen.
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
This trial tests if adding trilaciclib to standard chemotherapy after surgery can help people with hormone receptor-negative breast cancer. It aims to reduce side effects and improve treatment outcomes.
This trial tests whether taking trilaciclib alongside standard chemotherapy can help prevent low blood cell counts (myelosuppression) in people with limited-stage small cell lung cancer. It may help you stay stronger during treatment.
Hear when a new Trilaciclib trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.